Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study
Study context
- Population
- Paediatric lupus nephritis (LN) patients treated with mycophenolate mofetil (MMF) for induction therapy
- Participants
- 86 patients
- Outcome
- Relationship between mycophenolic acid (MPA) exposure (MPA-AUC) and disease response (renal remission)
- Follow-up
- 6 and 12 months
Methodological detailspopulation-based, limited sampling strategy for AUC, ROC analysis, Kaplan-Meier analysis
- Population-based
- Limited sampling strategy for AUC
- ROC analysis
- Kaplan-Meier analysis
Main finding
As reported in the abstract
MPA-AUC threshold for renal remission
MPA-AUC threshold for renal remission at 6 months
29.81 μg·h·mL-1
MPA-AUC threshold for renal remission at 12 months
30.63 μg·h·mL-1
Observational data: associations, not effects.
Further findings
MPA-AUC threshold for maintaining hypoactive state of LN · 6 and 12 months
μg·h·mL-1
- Threshold at 6 months
- 30.96
- Threshold at 12 months
- 31.19
Time to renal response or stable disease
- Patients reaching target MPA-AUC thresholds achieved renal response or stable disease earlier
Safety
MPA-AUC threshold for decreasing MMF-related adverse reactions
- Threshold
- 50.80 μg·h·mL-1
Original publication
Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study. Rheumatology (Oxford). Published 10 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →